<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lin Z</submitter><funding>Intramural NIH HHS</funding><funding>Medical Research Council</funding><funding>NCI NIH HHS</funding><pagination>1087-1097</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10690437</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>24(7)</volume><pubmed_abstract>Human leukocyte antigen (HLA)-E binds epitopes derived from HLA-A, HLA-B, HLA-C and HLA-G signal peptides (SPs) and serves as a ligand for CD94/NKG2A and CD94/NKG2C receptors expressed on natural killer and T cell subsets. We show that among 16 common classical HLA class I SP variants, only 6 can be efficiently processed to generate epitopes that enable CD94/NKG2 engagement, which we term 'functional SPs'. The single functional HLA-B SP, known as HLA-B/-21M, induced high HLA-E expression, but conferred the lowest receptor recognition. Consequently, HLA-B/-21M SP competes with other SPs for providing epitope to HLA-E and reduces overall recognition of target cells by CD94/NKG2A, calling for reassessment of previous disease models involving HLA-B/-21M. Genetic population data indicate a positive correlation between frequencies of functional SPs in humans and corresponding cytomegalovirus mimics, suggesting a means for viral escape from host responses. The systematic, quantitative approach described herein will facilitate development of prediction algorithms for accurately measuring the impact of CD94/NKG2-HLA-E interactions in disease resistance/susceptibility.</pubmed_abstract><journal>Nature immunology</journal><pubmed_title>HLA class I signal peptide polymorphism determines the level of CD94/NKG2-HLA-E-mediated regulation of effector cell responses.</pubmed_title><pmcid>PMC10690437</pmcid><funding_grant_id>MR/M019837/1</funding_grant_id><funding_grant_id>75N91019D00024</funding_grant_id><funding_grant_id>ZIA BC010792</funding_grant_id><pubmed_authors>Andresson T</pubmed_authors><pubmed_authors>Horowitz A</pubmed_authors><pubmed_authors>Das S</pubmed_authors><pubmed_authors>Hoelzemer A</pubmed_authors><pubmed_authors>Garcia-Beltran WF</pubmed_authors><pubmed_authors>Carrington M</pubmed_authors><pubmed_authors>Lin Z</pubmed_authors><pubmed_authors>Naranbhai V</pubmed_authors><pubmed_authors>Quastel M</pubmed_authors><pubmed_authors>Gillespie GM</pubmed_authors><pubmed_authors>Yuki Y</pubmed_authors><pubmed_authors>McMichael AJ</pubmed_authors><pubmed_authors>Bashirova AA</pubmed_authors><pubmed_authors>Akdag M</pubmed_authors><pubmed_authors>Garner L</pubmed_authors><pubmed_authors>Ojeda P</pubmed_authors><pubmed_authors>Kasprzak WK</pubmed_authors><pubmed_authors>Viard M</pubmed_authors><pubmed_authors>Beiersdorfer M</pubmed_authors></additional><is_claimable>false</is_claimable><name>HLA class I signal peptide polymorphism determines the level of CD94/NKG2-HLA-E-mediated regulation of effector cell responses.</name><description>Human leukocyte antigen (HLA)-E binds epitopes derived from HLA-A, HLA-B, HLA-C and HLA-G signal peptides (SPs) and serves as a ligand for CD94/NKG2A and CD94/NKG2C receptors expressed on natural killer and T cell subsets. We show that among 16 common classical HLA class I SP variants, only 6 can be efficiently processed to generate epitopes that enable CD94/NKG2 engagement, which we term 'functional SPs'. The single functional HLA-B SP, known as HLA-B/-21M, induced high HLA-E expression, but conferred the lowest receptor recognition. Consequently, HLA-B/-21M SP competes with other SPs for providing epitope to HLA-E and reduces overall recognition of target cells by CD94/NKG2A, calling for reassessment of previous disease models involving HLA-B/-21M. Genetic population data indicate a positive correlation between frequencies of functional SPs in humans and corresponding cytomegalovirus mimics, suggesting a means for viral escape from host responses. The systematic, quantitative approach described herein will facilitate development of prediction algorithms for accurately measuring the impact of CD94/NKG2-HLA-E interactions in disease resistance/susceptibility.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jul</publication><modification>2026-05-29T00:46:46.128Z</modification><creation>2025-04-05T11:45:29.016Z</creation></dates><accession>S-EPMC10690437</accession><cross_references><pubmed>37264229</pubmed><doi>10.1038/s41590-023-01523-z</doi></cross_references></HashMap>